Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?The Motley Fool • 07/21/24
FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the FirmPRNewsWire • 06/13/24
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesGlobeNewsWire • 05/09/24
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell ProgramGlobeNewsWire • 05/09/24
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual MeetingGlobeNewsWire • 05/03/24
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual MeetingGlobeNewsWire • 04/22/24
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private PlacementGlobeNewsWire • 03/19/24
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesGlobeNewsWire • 02/26/24
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 02/19/24
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 02/15/24
Fate Therapeutics (FATE) Soars 25.4%: Is Further Upside Left in the Stock?Zacks Investment Research • 01/30/24
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 12/13/23
Fate Therapeutics (FATE) Up 10.3% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/08/23